Kura Oncology Inc (NASDAQ:KURA) CFO Marc Grasso Sells 10,000 Shares

Kura Oncology Inc (NASDAQ:KURA) CFO Marc Grasso sold 10,000 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $26.00, for a total transaction of $260,000.00. Following the transaction, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at $260,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Marc Grasso also recently made the following trade(s):

  • On Tuesday, August 25th, Marc Grasso sold 10,000 shares of Kura Oncology stock. The shares were sold at an average price of $23.00, for a total transaction of $230,000.00.

Shares of Kura Oncology stock opened at $26.87 on Friday. The business has a fifty day simple moving average of $20.88 and a 200-day simple moving average of $15.48. The company has a quick ratio of 18.45, a current ratio of 18.45 and a debt-to-equity ratio of 0.02. Kura Oncology Inc has a 12 month low of $6.35 and a 12 month high of $28.00.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.02. As a group, equities research analysts expect that Kura Oncology Inc will post -1.66 EPS for the current year.

Large investors have recently made changes to their positions in the business. Swiss National Bank increased its stake in shares of Kura Oncology by 1.5% in the first quarter. Swiss National Bank now owns 65,900 shares of the company’s stock worth $656,000 after purchasing an additional 1,000 shares during the period. Ameritas Investment Partners Inc. boosted its stake in Kura Oncology by 64.2% during the second quarter. Ameritas Investment Partners Inc. now owns 4,686 shares of the company’s stock worth $76,000 after buying an additional 1,833 shares in the last quarter. Macquarie Group Ltd. acquired a new stake in Kura Oncology during the second quarter worth $31,000. Great West Life Assurance Co. Can boosted its stake in Kura Oncology by 127.4% during the second quarter. Great West Life Assurance Co. Can now owns 3,818 shares of the company’s stock worth $62,000 after buying an additional 2,139 shares in the last quarter. Finally, Parametric Portfolio Associates LLC boosted its stake in Kura Oncology by 25.0% during the first quarter. Parametric Portfolio Associates LLC now owns 13,062 shares of the company’s stock worth $130,000 after buying an additional 2,611 shares in the last quarter. 92.88% of the stock is owned by institutional investors.

A number of analysts have recently weighed in on KURA shares. Credit Suisse Group began coverage on shares of Kura Oncology in a research note on Tuesday, July 7th. They issued an “outperform” rating and a $27.00 price target for the company. Barclays lifted their price target on Kura Oncology from $24.00 to $32.00 and gave the company an “overweight” rating in a research report on Monday, August 31st. Brookline Capital Management restated a “buy” rating on shares of Kura Oncology in a report on Sunday, August 16th. Deutsche Bank decreased their target price on Kura Oncology from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Finally, Oppenheimer initiated coverage on Kura Oncology in a report on Sunday, May 31st. They issued a “buy” rating and a $27.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. Kura Oncology has a consensus rating of “Buy” and an average target price of $26.13.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Recommended Story: What’s a Black Swan?

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.